Bristol Myers' Experimental Psoriasis drug succeeds in late-stage study defeats rival Amgen's Otezla
Bristol Myers' experimental psoriasis drug, deucravacitinib has outmarched Amgen's Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial in patients with moderate to severe plaque psoriasis. Deucravacitinib (BMS-986165) is the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical trials across several immune-mediated diseases, involved in the mediation of the signaling of cytokines IL-23, IL-12, and Type I IFN.
The trial POETYK PSO-1 is the first of two global Phase III trials investigating the drug compared to...